Hepatocellular carcinoma in Budd-Chiari syndrome: A single center experience with long-term follow-up in South Korea

Table 2 Characteristics of the patients with hepatocellular carcinoma at the time point of diagnosis (n = 17)

Variables	HCC
Age (yr)	53 ± 12
Time period from BCS to HCC (mo)	51 ± 115
Child-Pugh class
A/B/C	6 (35.3)/8 (47.1)/3 (17.6)
Tumor stage (AJCC 6th)1
I/II/III/IV	8 (47.1)/6 (35.3)/3 (17.6)/0 (0)
Treatment modality
TACE/TACI	9 (52.9)
Intra-arterial chemotherapy	3 (17.6)
Conservative management	3 (17.6)
Operation	2 (11.9)
Prognosis
Alive	12 (70.5)
Death	3 (17.6)
F/U loss	2 (11.9)

Data were expressed as median ± IQR or n (%). BCS: Budd-Chiari syndrome; HCC: Hepatocellular carcinoma; TACE: Transarterial chemo-embolization; TACI: Transarterial chemo-infusion; F/U: Follow up; IQR: Interquartile range.

¹AJCC 6th, American Joint Committee on Cancer staging system, 6th edition.